21:42 , Oct 27, 2017 |  BC Week In Review  |  Company News

Incyte gains rights to Macrogenics' PD-1 inhibitor

MacroGenics Inc. (NASDAQ:MGNX) granted Incyte Corp. (NASDAQ:INCY) an exclusive, worldwide license to develop and commercialize PD-1 inhibitor MGA012 . MacroGenics retains rights to develop combinations that include the mAb and its pipeline assets. MacroGenics is...
21:31 , Oct 25, 2017 |  BC Extra  |  Company News

Incyte gains rights to MacroGenics' PD-1 inhibitor

MacroGenics Inc. (NASDAQ:MGNX) granted Incyte Corp. (NASDAQ:INCY) an exclusive, worldwide license to develop and commercialize PD-1 inhibitor MGA012 . MacroGenics, which retains rights to develop combinations that include the mAb and its pipeline assets, climbed...
07:00 , Aug 18, 2014 |  BC Week In Review  |  Company News

MacroGenics, Servier deal

MacroGenics will receive a $5 million milestone payment from Servier under a 2012 deal granting Servier an exclusive option to license rights to develop and commercialize MGD007 . The milestone was triggered by FDA’s approval...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Clinical News

MacroGenics preclinical data

In a mouse xenograft model of colorectal cancer, doses as low as 4 µg/kg IV MGD007 inhibited tumor growth. In cynomolgus monkeys, once-weekly doses of up to 200 µg/kg MGD007 for 4 weeks were well...
07:00 , Mar 22, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Imaging

Approach Summary Licensing status Publication and contact information Imaging In vivo synthetic chemistry for generating tumor-specific fluorescence and PET imaging agents An in vivo method for conducting selective chemical reactions in organisms could efficiently generate...